Delayed diagnosis of late-onset Pompe disease in patients with myopathies of unknown origin and/or hyperCKemia

Pompe disease is a rare metabolic myopathy whose diagnosis is sometimes delayed despite being essential for improving clinical outcomes. We aimed to investigate the prevalence of late-onset Pompe disease among patients with a myopathy of unknown etiology, including polymyositis, or with idiopathic r...

Full description

Saved in:
Bibliographic Details
Published inMolecular genetics and metabolism Vol. 114; no. 4; pp. 580 - 583
Main Authors Pérez-López, Jordi, Selva-O'Callaghan, Albert, Grau-Junyent, Josep M., Gallego-Galindo, Luis, Coll, M. Josep, García-Morillo, Salvador, Torralba-Cabeza, Miguel A., Vilardell-Tarrés, Miquel
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2015
Subjects
Online AccessGet full text
ISSN1096-7192
1096-7206
1096-7206
DOI10.1016/j.ymgme.2015.02.004

Cover

Abstract Pompe disease is a rare metabolic myopathy whose diagnosis is sometimes delayed despite being essential for improving clinical outcomes. We aimed to investigate the prevalence of late-onset Pompe disease among patients with a myopathy of unknown etiology, including polymyositis, or with idiopathic rise of creatine kinase (CK) levels, in a department of internal medicine. A cohort study was conducted in 241 subjects: 140 patients with myopathies of unknown origin or increased CK levels, 30 with polymyositis and 71 who constituted the control group of other myopathies. Acid α-glucosidase (GAA) activity was tested in dried blood spots. If a positive result was obtained, GAA activity in isolated lymphocytes and/or genetic testing was performed as a confirmatory diagnosis. Out of the 140 investigated patients, 2 patients with myopathies of unknown origin were confirmed to be positive for Pompe disease. Thus, late-onset Pompe disease should be considered among adult patients with myopathy of unknown origin. •2 out of 62 patients with unclassified myopathies were diagnosed with Pompe disease.•Diagnosis of LOPD should be considered among patients with myopathy of unknown origin.•1 patient showed a false DBS positive result; thus, the importance of confirmation.•Confirmation in lymphocytes or genetic analysis should follow a positive DBS test.
AbstractList Pompe disease is a rare metabolic myopathy whose diagnosis is sometimes delayed despite being essential for improving clinical outcomes. We aimed to investigate the prevalence of late-onset Pompe disease among patients with a myopathy of unknown etiology, including polymyositis, or with idiopathic rise of creatine kinase (CK) levels, in a department of internal medicine. A cohort study was conducted in 241 subjects: 140 patients with myopathies of unknown origin or increased CK levels, 30 with polymyositis and 71 who constituted the control group of other myopathies. Acid α-glucosidase (GAA) activity was tested in dried blood spots. If a positive result was obtained, GAA activity in isolated lymphocytes and/or genetic testing was performed as a confirmatory diagnosis. Out of the 140 investigated patients, 2 patients with myopathies of unknown origin were confirmed to be positive for Pompe disease. Thus, late-onset Pompe disease should be considered among adult patients with myopathy of unknown origin.Pompe disease is a rare metabolic myopathy whose diagnosis is sometimes delayed despite being essential for improving clinical outcomes. We aimed to investigate the prevalence of late-onset Pompe disease among patients with a myopathy of unknown etiology, including polymyositis, or with idiopathic rise of creatine kinase (CK) levels, in a department of internal medicine. A cohort study was conducted in 241 subjects: 140 patients with myopathies of unknown origin or increased CK levels, 30 with polymyositis and 71 who constituted the control group of other myopathies. Acid α-glucosidase (GAA) activity was tested in dried blood spots. If a positive result was obtained, GAA activity in isolated lymphocytes and/or genetic testing was performed as a confirmatory diagnosis. Out of the 140 investigated patients, 2 patients with myopathies of unknown origin were confirmed to be positive for Pompe disease. Thus, late-onset Pompe disease should be considered among adult patients with myopathy of unknown origin.
Pompe disease is a rare metabolic myopathy whose diagnosis is sometimes delayed despite being essential for improving clinical outcomes. We aimed to investigate the prevalence of late-onset Pompe disease among patients with a myopathy of unknown etiology, including polymyositis, or with idiopathic rise of creatine kinase (CK) levels, in a department of internal medicine. A cohort study was conducted in 241 subjects: 140 patients with myopathies of unknown origin or increased CK levels, 30 with polymyositis and 71 who constituted the control group of other myopathies. Acid α-glucosidase (GAA) activity was tested in dried blood spots. If a positive result was obtained, GAA activity in isolated lymphocytes and/or genetic testing was performed as a confirmatory diagnosis. Out of the 140 investigated patients, 2 patients with myopathies of unknown origin were confirmed to be positive for Pompe disease. Thus, late-onset Pompe disease should be considered among adult patients with myopathy of unknown origin. •2 out of 62 patients with unclassified myopathies were diagnosed with Pompe disease.•Diagnosis of LOPD should be considered among patients with myopathy of unknown origin.•1 patient showed a false DBS positive result; thus, the importance of confirmation.•Confirmation in lymphocytes or genetic analysis should follow a positive DBS test.
Pompe disease is a rare metabolic myopathy whose diagnosis is sometimes delayed despite being essential for improving clinical outcomes. We aimed to investigate the prevalence of late-onset Pompe disease among patients with a myopathy of unknown etiology, including polymyositis, or with idiopathic rise of creatine kinase (CK) levels, in a department of internal medicine. A cohort study was conducted in 241 subjects: 140 patients with myopathies of unknown origin or increased CK levels, 30 with polymyositis and 71 who constituted the control group of other myopathies. Acid α-glucosidase (GAA) activity was tested in dried blood spots. If a positive result was obtained, GAA activity in isolated lymphocytes and/or genetic testing was performed as a confirmatory diagnosis. Out of the 140 investigated patients, 2 patients with myopathies of unknown origin were confirmed to be positive for Pompe disease. Thus, late-onset Pompe disease should be considered among adult patients with myopathy of unknown origin.
Author Gallego-Galindo, Luis
Selva-O'Callaghan, Albert
García-Morillo, Salvador
Pérez-López, Jordi
Vilardell-Tarrés, Miquel
Grau-Junyent, Josep M.
Coll, M. Josep
Torralba-Cabeza, Miguel A.
Author_xml – sequence: 1
  givenname: Jordi
  surname: Pérez-López
  fullname: Pérez-López, Jordi
  email: jordpere@vhebron.net
  organization: Department of Internal Medicine, Hospital Vall d'Hebron, 119-129, 08035, Barcelona, Spain
– sequence: 2
  givenname: Albert
  surname: Selva-O'Callaghan
  fullname: Selva-O'Callaghan, Albert
  email: aselva@vhebron.net
  organization: Department of Internal Medicine, Hospital Vall d'Hebron, 119-129, 08035, Barcelona, Spain
– sequence: 3
  givenname: Josep M.
  surname: Grau-Junyent
  fullname: Grau-Junyent, Josep M.
  email: JMGRAU@clinic.ub.es
  organization: Department of Internal Medicine, Hospital Clínic, Carrer Villarroel, 170, 08036, Barcelona, Spain
– sequence: 4
  givenname: Luis
  surname: Gallego-Galindo
  fullname: Gallego-Galindo, Luis
  email: lugallego@vhebron.net
  organization: Department of Internal Medicine, Hospital Vall d'Hebron, 119-129, 08035, Barcelona, Spain
– sequence: 5
  givenname: M. Josep
  surname: Coll
  fullname: Coll, M. Josep
  email: mjcoll@clinic.ub.es
  organization: Department of Biochemistry and Molecular Genetics, Hospital Clínic, Carrer Villarroel, 170, 08036, Barcelona, Spain
– sequence: 6
  givenname: Salvador
  surname: García-Morillo
  fullname: García-Morillo, Salvador
  email: salvaymar@gmail.com
  organization: Department of Internal Medicine, Hospital Virgen del Rocío, Avenida Manuel Siurot, s/n, 41013, Sevilla, Spain
– sequence: 7
  givenname: Miguel A.
  orcidid: 0000-0002-0451-3597
  surname: Torralba-Cabeza
  fullname: Torralba-Cabeza, Miguel A.
  email: mantorralba@gmail.com
  organization: Department of Internal Medicine, Hospital Lozano Blesa, Avenida San Juan Bosco, 15, 50009 Zaragoza, Spain
– sequence: 8
  givenname: Miquel
  surname: Vilardell-Tarrés
  fullname: Vilardell-Tarrés, Miquel
  email: mvilardell@vhebron.net
  organization: Department of Internal Medicine, Hospital Vall d'Hebron, 119-129, 08035, Barcelona, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25752415$$D View this record in MEDLINE/PubMed
BookMark eNp9kb1uHCEUhVHkyH_xE0SKKNPMGNgBdooU0ebHVizFhVMjFi67bGZgAmyseftgr7dJ4eqiy_fd4pwLdBJiAITeU9JSQsX1rp3HzQgtI5S3hLWEdG_QOSW9aCQj4uT4pj07Qxc57wihlPfdKTpjXHLWUX6OwhcY9AwWW683IWafcXR40AWaGDIUfB_HCepvBp0B-4AnXTyEkvGjL1s8zrEuth6evX34HeJjwDH5TUV1sNcx4e08QVr9gNHrd-it00OGq5d5iX59-_qwumnufn6_XX2-a8yC96Wh3BApxFovtQRwDoRlZmEJEYRwLZ12S22pYB0I2UkuqeRraZdOOs57kHxxiT4e7k4p_tlDLmr02cAw6ABxnxUVkjJGJF1W9MMLul-PYNWU_KjTrI4ZVaA_ACbFnBM4ZXypIcRQkvaDokQ99aF26rkP9dSHIkzVPqq7-M89nn_d-nSwoEb010NS2dTMDVifwBRlo3_V_wfhgqZx
CitedBy_id crossref_primary_10_1038_s41573_019_0036_1
crossref_primary_10_1016_j_ymgme_2016_12_004
crossref_primary_10_1212_NXG_0000000000000623
crossref_primary_10_1016_j_rcreue_2017_10_003
crossref_primary_10_1590_0004_282x20180018
crossref_primary_10_3389_fneur_2022_965207
crossref_primary_10_3233_JND_220819
crossref_primary_10_1016_j_rcreu_2017_10_005
crossref_primary_10_1136_jclinpath_2018_205446
crossref_primary_10_1016_S1286_935X_17_86068_8
crossref_primary_10_1080_21678707_2016_1229180
crossref_primary_10_1007_s11696_018_0623_3
crossref_primary_10_3233_JND_180336
crossref_primary_10_1016_j_ymgme_2017_10_008
crossref_primary_10_1186_s13023_023_02887_z
crossref_primary_10_1055_s_0040_1714099
crossref_primary_10_1007_s00415_017_8686_6
crossref_primary_10_1016_j_med_2017_03_005
crossref_primary_10_1097_CND_0000000000000269
crossref_primary_10_1016_j_nmd_2017_12_008
crossref_primary_10_1212_WNL_0000000000002758
crossref_primary_10_4103_0028_3886_325313
crossref_primary_10_1016_j_nmd_2017_03_010
crossref_primary_10_1111_ane_13133
crossref_primary_10_1002_mus_25478
crossref_primary_10_1136_jclinpath_2019_205711
crossref_primary_10_17116_jnevro201511511219_24
Cites_doi 10.1007/s10545-010-9201-8
10.1016/j.ymgme.2012.05.007
10.1212/WNL.61.3.288
10.1016/j.ymgme.2007.09.006
10.1007/s10545-012-9451-8
10.1203/PDR.0b013e3181b24e94
10.1186/1750-1172-8-49
10.1056/NEJMoa0909859
10.1007/s00415-011-6293-5
10.1186/1750-1172-7-73
10.1016/S0140-6736(08)61555-X
10.1093/clinchem/47.8.1378
10.1016/j.nmd.2011.04.001
10.1007/s00415-009-5275-3
10.1097/01.gim.0000218152.87434.f3
10.1016/j.ymgme.2013.03.002
10.1007/s10545-011-9404-7
10.1016/j.ymgme.2013.08.005
10.1007/s10545-009-9003-z
10.1016/j.ymgme.2007.05.011
10.1212/WNL.52.4.851
ContentType Journal Article
Copyright 2015 Elsevier Inc.
Copyright © 2015 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2015 Elsevier Inc.
– notice: Copyright © 2015 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.ymgme.2015.02.004
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
Biology
EISSN 1096-7206
EndPage 583
ExternalDocumentID 25752415
10_1016_j_ymgme_2015_02_004
S1096719215000475
Genre Research Support, Non-U.S. Gov't
Journal Article
Case Reports
GroupedDBID ---
--K
--M
-~X
.55
.GJ
.~1
0R~
123
1B1
1RT
1~.
1~5
29M
4.4
457
4G.
53G
5RE
5VS
7-5
71M
8P~
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAXUO
ABFNM
ABFRF
ABGSF
ABJNI
ABMAC
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGRDE
AGUBO
AGYEJ
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
CAG
COF
CS3
DM4
DOVZS
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
LG5
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SDF
SDG
SDP
SES
SEW
SPCBC
SSU
SSZ
T5K
X7M
XPP
ZA5
ZGI
ZMT
ZU3
~G-
~KM
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
BNPGV
CITATION
SSH
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ACLOT
EFKBS
~HD
ID FETCH-LOGICAL-c359t-15c0766ba8a7eeffe6d2c3d006005a7faf8ad1624e674757175b7d8f7f559e753
IEDL.DBID .~1
ISSN 1096-7192
1096-7206
IngestDate Sun Sep 28 09:52:36 EDT 2025
Thu Apr 03 07:09:12 EDT 2025
Tue Jul 01 03:08:37 EDT 2025
Thu Apr 24 23:10:16 EDT 2025
Fri Feb 23 02:22:47 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Alpha glucosidase
Maltase deficiency
Pompe disease
Idiopathic hyperCKemia
Myopathy
Language English
License Copyright © 2015 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c359t-15c0766ba8a7eeffe6d2c3d006005a7faf8ad1624e674757175b7d8f7f559e753
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ORCID 0000-0002-0451-3597
PMID 25752415
PQID 1671220718
PQPubID 23479
PageCount 4
ParticipantIDs proquest_miscellaneous_1671220718
pubmed_primary_25752415
crossref_citationtrail_10_1016_j_ymgme_2015_02_004
crossref_primary_10_1016_j_ymgme_2015_02_004
elsevier_sciencedirect_doi_10_1016_j_ymgme_2015_02_004
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2015
2015-04-00
2015-Apr
20150401
PublicationDateYYYYMMDD 2015-04-01
PublicationDate_xml – month: 04
  year: 2015
  text: April 2015
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular genetics and metabolism
PublicationTitleAlternate Mol Genet Metab
PublicationYear 2015
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Bembi, Pisa, Confalonieri (bb0040) Dec 2010; 33
Umapathysivam, Hopwood, Meikle (bb0100) Aug 2001; 47
Lukacs, Nieves Cobos, Mengel (bb0070) Feb 2010; 33
van der Ploeg, Reuser (bb0010) Oct 11 2008; 372
Hobson-Webb, Proia, Thurberg (bb0090) Aug 2012; 106
Gort, Coll, Chabas (bb0075) Sep-Oct 2007; 92
Gungor, Kruijshaar, Plug (bb0065) Mar 27 2013; 8
Preisler, Lukacs, Vinge (bb0110) Nov 2013; 110
Regnery, Kornblum, Hanisch (bb0055) Sep 2012; 35
van der Ploeg, Clemens, Corzo (bb0060) Apr 15 2010; 362
Engel, Hirschhorn, Huie (bb0015) 2004
Angelini, Semplicini, Ravaglia (bb0045) May 2012; 259
Kishnani, Steiner, Bali (bb0080) May 2006; 8
Ausems, Lochman, van Diggelen (bb0085) Mar 10 1999; 52
Pompe Disease Diagnostic Working G, Winchester, Bali (bb0105) Mar 2008; 93
Hirschhorn, Reuser (bb0005) 2001
Spada, Porta, Vercelli (bb0115) Jun 2013; 109
Orlikowski, Pellegrini, Prigent (bb0050) Jul 2011; 21
van Gelder, van Capelle, Ebbink (bb0025) May 2012; 35
Kishnani, Corzo, Leslie (bb0020) Sep 2009; 66
de Vries, van der Beek, Hop (bb0030) 2012; 7
Amato, Griggs (bb0095) Aug 12 2003; 61
Strothotte, Strigl-Pill, Grunert (bb0035) Jan 2010; 257
van Gelder (10.1016/j.ymgme.2015.02.004_bb0025) 2012; 35
Hirschhorn (10.1016/j.ymgme.2015.02.004_bb0005) 2001
Pompe Disease Diagnostic Working G (10.1016/j.ymgme.2015.02.004_bb0105) 2008; 93
Umapathysivam (10.1016/j.ymgme.2015.02.004_bb0100) 2001; 47
Bembi (10.1016/j.ymgme.2015.02.004_bb0040) 2010; 33
Regnery (10.1016/j.ymgme.2015.02.004_bb0055) 2012; 35
Engel (10.1016/j.ymgme.2015.02.004_bb0015) 2004
Gort (10.1016/j.ymgme.2015.02.004_bb0075) 2007; 92
Kishnani (10.1016/j.ymgme.2015.02.004_bb0080) 2006; 8
van der Ploeg (10.1016/j.ymgme.2015.02.004_bb0010) 2008; 372
de Vries (10.1016/j.ymgme.2015.02.004_bb0030) 2012; 7
van der Ploeg (10.1016/j.ymgme.2015.02.004_bb0060) 2010; 362
Lukacs (10.1016/j.ymgme.2015.02.004_bb0070) 2010; 33
Ausems (10.1016/j.ymgme.2015.02.004_bb0085) 1999; 52
Hobson-Webb (10.1016/j.ymgme.2015.02.004_bb0090) 2012; 106
Kishnani (10.1016/j.ymgme.2015.02.004_bb0020) 2009; 66
Strothotte (10.1016/j.ymgme.2015.02.004_bb0035) 2010; 257
Orlikowski (10.1016/j.ymgme.2015.02.004_bb0050) 2011; 21
Amato (10.1016/j.ymgme.2015.02.004_bb0095) 2003; 61
Angelini (10.1016/j.ymgme.2015.02.004_bb0045) 2012; 259
Preisler (10.1016/j.ymgme.2015.02.004_bb0110) 2013; 110
Spada (10.1016/j.ymgme.2015.02.004_bb0115) 2013; 109
Gungor (10.1016/j.ymgme.2015.02.004_bb0065) 2013; 8
References_xml – year: 2004
  ident: bb0015
  article-title: Acid maltase deficiency
  publication-title: Myology
– volume: 33
  start-page: 43
  year: Feb 2010
  end-page: 50
  ident: bb0070
  article-title: Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possibility for newborn screening
  publication-title: J. Inherit. Metab. Dis.
– volume: 109
  start-page: 171
  year: Jun 2013
  end-page: 173
  ident: bb0115
  article-title: Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia
  publication-title: Mol. Genet. Metab.
– volume: 93
  start-page: 275
  year: Mar 2008
  end-page: 281
  ident: bb0105
  article-title: Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting
  publication-title: Mol. Genet. Metab.
– volume: 8
  start-page: 49
  year: Mar 27 2013
  ident: bb0065
  article-title: Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study
  publication-title: Orphanet J. Rare Dis.
– volume: 372
  start-page: 1342
  year: Oct 11 2008
  end-page: 1353
  ident: bb0010
  article-title: Pompe's disease
  publication-title: Lancet
– volume: 52
  start-page: 851
  year: Mar 10 1999
  end-page: 853
  ident: bb0085
  article-title: A diagnostic protocol for adult-onset glycogen storage disease type II
  publication-title: Neurology
– volume: 47
  start-page: 1378
  year: Aug 2001
  end-page: 1383
  ident: bb0100
  article-title: Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease
  publication-title: Clin. Chem.
– volume: 61
  start-page: 288
  year: Aug 12 2003
  end-page: 289
  ident: bb0095
  article-title: Unicorns, dragons, polymyositis, and other mythological beasts
  publication-title: Neurology
– volume: 66
  start-page: 329
  year: Sep 2009
  end-page: 335
  ident: bb0020
  article-title: Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease
  publication-title: Pediatr. Res.
– volume: 35
  start-page: 505
  year: May 2012
  end-page: 511
  ident: bb0025
  article-title: Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy
  publication-title: J. Inherit. Metab. Dis.
– volume: 110
  start-page: 287
  year: Nov 2013
  end-page: 289
  ident: bb0110
  article-title: Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies
  publication-title: Mol. Genet. Metab.
– volume: 7
  start-page: 73
  year: 2012
  ident: bb0030
  article-title: Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study
  publication-title: Orphanet J. Rare Dis.
– volume: 21
  start-page: 477
  year: Jul 2011
  end-page: 482
  ident: bb0050
  article-title: Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease
  publication-title: Neuromuscul. Disord.
– volume: 92
  start-page: 183
  year: Sep-Oct 2007
  end-page: 187
  ident: bb0075
  article-title: Glycogen storage disease type II in Spanish patients: high frequency of c.1076-1G
  publication-title: Mol. Genet. Metab.
– volume: 259
  start-page: 952
  year: May 2012
  end-page: 958
  ident: bb0045
  article-title: Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4
  publication-title: J. Neurol.
– volume: 35
  start-page: 837
  year: Sep 2012
  end-page: 845
  ident: bb0055
  article-title: 36
  publication-title: J. Inherit. Metab. Dis.
– volume: 362
  start-page: 1396
  year: Apr 15 2010
  end-page: 1406
  ident: bb0060
  article-title: A randomized study of alglucosidase alfa in late-onset Pompe's disease
  publication-title: N. Engl. J. Med.
– volume: 106
  start-page: 462
  year: Aug 2012
  end-page: 469
  ident: bb0090
  article-title: Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature
  publication-title: Mol. Genet. Metab.
– volume: 257
  start-page: 91
  year: Jan 2010
  end-page: 97
  ident: bb0035
  article-title: Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial
  publication-title: J. Neurol.
– volume: 33
  start-page: 727
  year: Dec 2010
  end-page: 735
  ident: bb0040
  article-title: Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II
  publication-title: J. Inherit. Metab. Dis.
– start-page: 3389
  year: 2001
  end-page: 3420
  ident: bb0005
  article-title: Glycogen storage disease type II: acid alphaglucosidase (acid maltase) deficiency
  publication-title: The Metabolic and Molecular Bases of Inherited Disease
– volume: 8
  start-page: 267
  year: May 2006
  end-page: 288
  ident: bb0080
  article-title: Pompe disease diagnosis and management guideline
  publication-title: Genet. Med.
– volume: 33
  start-page: 727
  issue: 6
  year: 2010
  ident: 10.1016/j.ymgme.2015.02.004_bb0040
  article-title: Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II
  publication-title: J. Inherit. Metab. Dis.
  doi: 10.1007/s10545-010-9201-8
– volume: 106
  start-page: 462
  issue: 4
  year: 2012
  ident: 10.1016/j.ymgme.2015.02.004_bb0090
  article-title: Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature
  publication-title: Mol. Genet. Metab.
  doi: 10.1016/j.ymgme.2012.05.007
– volume: 61
  start-page: 288
  issue: 3
  year: 2003
  ident: 10.1016/j.ymgme.2015.02.004_bb0095
  article-title: Unicorns, dragons, polymyositis, and other mythological beasts
  publication-title: Neurology
  doi: 10.1212/WNL.61.3.288
– volume: 93
  start-page: 275
  issue: 3
  year: 2008
  ident: 10.1016/j.ymgme.2015.02.004_bb0105
  article-title: Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting
  publication-title: Mol. Genet. Metab.
  doi: 10.1016/j.ymgme.2007.09.006
– volume: 35
  start-page: 837
  issue: 5
  year: 2012
  ident: 10.1016/j.ymgme.2015.02.004_bb0055
  article-title: 36months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy
  publication-title: J. Inherit. Metab. Dis.
  doi: 10.1007/s10545-012-9451-8
– start-page: 3389
  year: 2001
  ident: 10.1016/j.ymgme.2015.02.004_bb0005
  article-title: Glycogen storage disease type II: acid alphaglucosidase (acid maltase) deficiency
– volume: 66
  start-page: 329
  issue: 3
  year: 2009
  ident: 10.1016/j.ymgme.2015.02.004_bb0020
  article-title: Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease
  publication-title: Pediatr. Res.
  doi: 10.1203/PDR.0b013e3181b24e94
– volume: 8
  start-page: 49
  issue: 1
  year: 2013
  ident: 10.1016/j.ymgme.2015.02.004_bb0065
  article-title: Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study
  publication-title: Orphanet J. Rare Dis.
  doi: 10.1186/1750-1172-8-49
– volume: 362
  start-page: 1396
  issue: 15
  year: 2010
  ident: 10.1016/j.ymgme.2015.02.004_bb0060
  article-title: A randomized study of alglucosidase alfa in late-onset Pompe's disease
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0909859
– volume: 259
  start-page: 952
  issue: 5
  year: 2012
  ident: 10.1016/j.ymgme.2015.02.004_bb0045
  article-title: Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4years
  publication-title: J. Neurol.
  doi: 10.1007/s00415-011-6293-5
– volume: 7
  start-page: 73
  year: 2012
  ident: 10.1016/j.ymgme.2015.02.004_bb0030
  article-title: Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study
  publication-title: Orphanet J. Rare Dis.
  doi: 10.1186/1750-1172-7-73
– volume: 372
  start-page: 1342
  issue: 9646
  year: 2008
  ident: 10.1016/j.ymgme.2015.02.004_bb0010
  article-title: Pompe's disease
  publication-title: Lancet
  doi: 10.1016/S0140-6736(08)61555-X
– volume: 47
  start-page: 1378
  issue: 8
  year: 2001
  ident: 10.1016/j.ymgme.2015.02.004_bb0100
  article-title: Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease
  publication-title: Clin. Chem.
  doi: 10.1093/clinchem/47.8.1378
– year: 2004
  ident: 10.1016/j.ymgme.2015.02.004_bb0015
  article-title: Acid maltase deficiency
– volume: 21
  start-page: 477
  issue: 7
  year: 2011
  ident: 10.1016/j.ymgme.2015.02.004_bb0050
  article-title: Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease
  publication-title: Neuromuscul. Disord.
  doi: 10.1016/j.nmd.2011.04.001
– volume: 257
  start-page: 91
  issue: 1
  year: 2010
  ident: 10.1016/j.ymgme.2015.02.004_bb0035
  article-title: Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial
  publication-title: J. Neurol.
  doi: 10.1007/s00415-009-5275-3
– volume: 8
  start-page: 267
  issue: 5
  year: 2006
  ident: 10.1016/j.ymgme.2015.02.004_bb0080
  article-title: Pompe disease diagnosis and management guideline
  publication-title: Genet. Med.
  doi: 10.1097/01.gim.0000218152.87434.f3
– volume: 109
  start-page: 171
  issue: 2
  year: 2013
  ident: 10.1016/j.ymgme.2015.02.004_bb0115
  article-title: Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia
  publication-title: Mol. Genet. Metab.
  doi: 10.1016/j.ymgme.2013.03.002
– volume: 35
  start-page: 505
  issue: 3
  year: 2012
  ident: 10.1016/j.ymgme.2015.02.004_bb0025
  article-title: Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy
  publication-title: J. Inherit. Metab. Dis.
  doi: 10.1007/s10545-011-9404-7
– volume: 110
  start-page: 287
  issue: 3
  year: 2013
  ident: 10.1016/j.ymgme.2015.02.004_bb0110
  article-title: Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies
  publication-title: Mol. Genet. Metab.
  doi: 10.1016/j.ymgme.2013.08.005
– volume: 33
  start-page: 43
  issue: 1
  year: 2010
  ident: 10.1016/j.ymgme.2015.02.004_bb0070
  article-title: Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possibility for newborn screening
  publication-title: J. Inherit. Metab. Dis.
  doi: 10.1007/s10545-009-9003-z
– volume: 92
  start-page: 183
  issue: 1–2
  year: 2007
  ident: 10.1016/j.ymgme.2015.02.004_bb0075
  article-title: Glycogen storage disease type II in Spanish patients: high frequency of c.1076-1G>C mutation
  publication-title: Mol. Genet. Metab.
  doi: 10.1016/j.ymgme.2007.05.011
– volume: 52
  start-page: 851
  issue: 4
  year: 1999
  ident: 10.1016/j.ymgme.2015.02.004_bb0085
  article-title: A diagnostic protocol for adult-onset glycogen storage disease type II
  publication-title: Neurology
  doi: 10.1212/WNL.52.4.851
SSID ssj0011594
Score 2.2273288
Snippet Pompe disease is a rare metabolic myopathy whose diagnosis is sometimes delayed despite being essential for improving clinical outcomes. We aimed to...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 580
SubjectTerms Adult
Alpha glucosidase
alpha-Glucosidases - blood
Cohort Studies
Creatine Kinase - genetics
Creatine Kinase - metabolism
Delayed Diagnosis
Dried Blood Spot Testing
Female
Genetic Testing
Glycogen Storage Disease Type II - diagnosis
Humans
Idiopathic hyperCKemia
Maltase deficiency
Middle Aged
Muscular Diseases - etiology
Muscular Diseases - genetics
Mutation
Myopathy
Polymyositis - etiology
Polymyositis - genetics
Pompe disease
Title Delayed diagnosis of late-onset Pompe disease in patients with myopathies of unknown origin and/or hyperCKemia
URI https://dx.doi.org/10.1016/j.ymgme.2015.02.004
https://www.ncbi.nlm.nih.gov/pubmed/25752415
https://www.proquest.com/docview/1671220718
Volume 114
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1096-7206
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011594
  issn: 1096-7192
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Complete Freedom Collection [SCCMFC]
  customDbUrl:
  eissn: 1096-7206
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011594
  issn: 1096-7192
  databaseCode: ACRLP
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1096-7206
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011594
  issn: 1096-7192
  databaseCode: .~1
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals [SCFCJ]
  customDbUrl:
  eissn: 1096-7206
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011594
  issn: 1096-7192
  databaseCode: AIKHN
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1096-7206
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011594
  issn: 1096-7192
  databaseCode: AKRWK
  dateStart: 19980101
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB5EEb2Ib9cXEcSTdbePJPW4rsqqKIIK3kLaprqym8o-DnvxtzuTtgse9OCtLZM2dKbJN8nXbwCOk5SqHonQk7GvPcT_3NMxfo86zKPzwGjNE9rRvX8Q3Zfo9pW_zkGn_heGaJXV2F-O6W60rq40q7fZ_Oz1mk8-om9Jcl6k6R9J-tGc1L8wps--ZjQPBDyuGCIZe2RdKw85jtd08DYgrUyfl8Kd0W-z02_o081C16uwUsFH1i57uAZzxq7DRtti6jyYshPmCJ1upXwdFi_qo6VOXdZtA-yl6eupyVhWkux6I1bkrI-Q0yNi9Zg9EpJm1cYN61lWSa-OGK3ZssG0cFWMjWs3sbQoZ1lZX4tpmzWLIXvH5HbYucNn6k14ub567nS9quiCl4b8fOz5PG1JIRIda2mIUyKyIA0z0m1pcS1zncc680UQGYGZCMdskCcyi3OZY25iMPnZgnlbWLMDTIYi8tEYb5ejY1LEIjKNtUbzMGlx3oCgftkqrRTJqTBGX9XUsw_lPKTIQ6oVKPRQA05njT5LQY6_zUXtRfUjrhROGX83PKp9rtBDtI2irSkmI-Vj1AUBQrO4AdtlMMx6ggMgJ0y0-9_H7sEynZXcoH2YHw8n5gBhzzg5dHF9CAvtm7vuwzcJdQEC
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB5BEYLLapdnl30YCXEiavOwHY7d7qKyhQoJkLhZTuKwXbUO6uPQf8-M41TaAxz2FiXj2PI44288k28AzrKcqh6JOJBpqAPE_zzQKX6POi6Ty8hozTOK6N6OxOAx-f3Enzag3_wLQ2mV3vbXNt1Za3-n42ez8zIed-5DRN-S6LyI0z-RfBO2Eo42uQVbvevhYLQOJuCO7YLLKB9Qg4Z8yKV5rabPU6LLDHnN3Zm8tUG9BUDdRnT1ET54BMl69SA_wYaxe7Dfs-g9T1fsnLmcTndYvgfbP5qrnX5T2W0f7E8z0StTsKLOsxvPWVWyCaLOgHKrF-yOwDTzsRs2tsyzr84ZHduy6apyhYyNa7e0dC5nWV1ii2lbdKoZ-4P-7aw_xD71ATxe_XroDwJfdyHIY365CEKed6UQmU61NJRWIooojwuibulyLUtdproIRZQYgc4IR4eQZ7JIS1mie2LQ_zmElq2sOQYmY5GEKIyvKxPBc4QjMk-1RvE463LehqiZbJV7UnKqjTFRTfbZX-U0pEhDqhsp1FAbLtaNXmpOjvfFRaNF9c_SUrhrvN_wtNG5Qg1RJEVbUy3nKsSFF0WIztI2HNWLYT0StIGcYNHn_-32O-wMHm5v1M31aHgCu_SkThX6Aq3FbGm-IgpaZN_8Kn8FwUUDrQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Delayed+diagnosis+of+late-onset+Pompe+disease+in+patients+with+myopathies+of+unknown+origin+and%2For+hyperCKemia&rft.jtitle=Molecular+genetics+and+metabolism&rft.au=P%C3%A9rez-L%C3%B3pez%2C+Jordi&rft.au=Selva-O%27Callaghan%2C+Albert&rft.au=Grau-Junyent%2C+Josep+M&rft.au=Gallego-Galindo%2C+Luis&rft.date=2015-04-01&rft.issn=1096-7206&rft.eissn=1096-7206&rft.volume=114&rft.issue=4&rft.spage=580&rft_id=info:doi/10.1016%2Fj.ymgme.2015.02.004&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1096-7192&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1096-7192&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1096-7192&client=summon